A
ALZN
Alzamend Neuro, Inc. Common Stock
$1.35
Current Price
1W
1M
3M
6M
1Y
All
AI analysis
Read what the AI thinks of Alzamend Neuro, Inc. Common Stock in the app.
Analyses are generated by AI from public data and are not investment advice.
Get the app
Key figures
Dividend per share
—
Yield
—
EPS
-$2.27
P/E
—
Data as of Oct 8
Why it matters for the long term
Over 10-20 years, what drives a share up is the growth of its profits (EPS) + reinvested dividends. The P/E tells you whether you are paying a lot or a little for that growth. In short: rising EPS + reasonable P/E + growing dividend = good long-term candidate.
Upcoming events
Quarterly earnings
Expected EPS: -$0.23
Dec 7
Posts
No posts about ALZN yet.
About Alzamend Neuro, Inc. Common Stock
Alzamend Neuro is a small clinical-stage biotechnology company developing treatments for Alzheimer's disease, bipolar disorder, and other brain conditions. It has no approved products and no sales. The company spends money on research and trials and hopes a drug eventually wins approval or a partner buys the rights.